Cargando…
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
Sorafenib is still the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC). In recent years, several investigational agents mainly targeting angiogenesis failed in late-phase clinical development due to either toxicity or lack of benefit. Recently, data of the RE...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036543/ https://www.ncbi.nlm.nih.gov/pubmed/27703962 http://dx.doi.org/10.2147/JHC.S112537 |